drug · small molecule
naltrexone hydrochloride
Marketedupdated 3mo agoby Biostax Corp🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for pain and 7 investigational indications.
targets
Opioid receptors; mu/kappa/delta
all catalysts(0)
nothing on the calendar yet
Trials studying naltrexone hydrochloride
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 12, 2027
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Dec 12, 2027formulationUS 78159341.3y
- Dec 12, 2027formulationUS 78159341.3y
- Dec 12, 2027formulationUS 78159341.3y
- Dec 12, 2027formulationUS 78159341.3y
- Dec 12, 2027formulationUS 78159341.3y
- Dec 12, 2027formulationUS 78159341.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that